Tachyum Prodigy Complete Software Package Enters Testing
LAS VEGAS–(BUSINESS WIRE)–#Linux—Tachyum® today announced that it has completed development of the software stack for…
News
ISN® Introduces New Proprietary AI Engine, InsightAI
InsightAI harnesses the power of Generative AI to help ISN customers discover insights from large…
Healthcare Leaders Cite Automation, Worker Burnout as Top Drivers of Technology Integrations, MGMA and Laserfiche Study Finds
LONG BEACH, Calif.–(BUSINESS WIRE)–#Laserfiche–New research by Medical Group Management Association (MGMA) and Laserfiche — the…
Helix Enhances Cardholder Experience and Increases Fraud Protection With New Cooperative Authorization Solution
New authorization solution enables clients to personalize their cardholder experiences and improve profitability for qualified…
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN…
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol…
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus…
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver based…
Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline…
New Clinical Data Demonstrate that QSYMIA®, the Leading Once-Daily Oral Weight-Management Medication, Reduces Blood Pressure
CAMPBELL, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — VIVUS LLC, a biopharmaceutical company committed to…
SciSparc Adopts Limited Duration Shareholder Rights Plan
TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company…
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a company focused on developing novel precision…
Vaxcyte Appoints Jacks Lee to Board of Directors
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine…
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in…
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
The pre- clinical trial conducted using the combined treatment of SciSparc’s proprietary CannAmide™ and Clearmind…
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation,…
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no…
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
Now seeking out license opportunities for SYMJEPI® SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) —…